• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血管生成素-2增强视网膜血管对血管内皮生长因子的敏感性。

Angiopoietin-2 enhances retinal vessel sensitivity to vascular endothelial growth factor.

作者信息

Oshima Yuji, Deering Tye, Oshima Sachiko, Nambu Hiroyuki, Reddy P Seshidhar, Kaleko Michael, Connelly Sheila, Hackett Sean F, Campochiaro Peter A

机构信息

Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA.

出版信息

J Cell Physiol. 2004 Jun;199(3):412-7. doi: 10.1002/jcp.10442.

DOI:10.1002/jcp.10442
PMID:15095288
Abstract

Increased expression of vascular endothelial growth factor (VEGF) in the retina starting after postnatal day (P)7 results in neovascularization originating from deep retinal capillaries, but not those in the superficial capillary bed. Doxycycline was administered starting P0 to double transgenic mice with inducible expression of VEGF in the retina. These mice showed proliferation and dilation of superficial retinal capillaries, indicating that at this stage of development, the superficial capillaries are sensitive to the effects of VEGF. Angiopoietin-2 (Ang2) is expressed along the surface of the retina for several days after birth, but by P7 and later, Ang2 is only expressed in the region of the deep capillary bed. In mice with ubiquitous doxycycline-inducible expression of Ang2, in the absence of doxycycline, intravitreous injection of a gutless adenoviral vector expressing VEGF (AGV.VEGF) resulted in neovascularization of the cornea and iris, but no retinal neovascularization. After treatment with doxycycline to induce Ang2 expression, intravitreous injection of AGV.VEGF caused retinal neovascularization in addition to corneal and iris neovascularization. The retinal neovascularization originated from both the superficial and deep capillary beds. These data suggest that Ang2 promotes sensitivity to the angiogenic effects of VEGF in retinal vessels.

摘要

出生后第7天(P7)开始,视网膜中血管内皮生长因子(VEGF)表达增加会导致源自视网膜深层毛细血管而非浅层毛细血管床的新生血管形成。从出生后第0天(P0)开始对视网膜中VEGF可诱导表达的双转基因小鼠给予强力霉素。这些小鼠表现出视网膜浅层毛细血管的增殖和扩张,表明在这个发育阶段,浅层毛细血管对VEGF的作用敏感。血管生成素-2(Ang2)在出生后几天沿视网膜表面表达,但到P7及以后,Ang2仅在深层毛细血管床区域表达。在Ang2可通过强力霉素普遍诱导表达的小鼠中,在未使用强力霉素的情况下,玻璃体内注射表达VEGF的无内脏腺病毒载体(AGV.VEGF)会导致角膜和虹膜新生血管形成,但不会导致视网膜新生血管形成。在用强力霉素诱导Ang2表达后,玻璃体内注射AGV.VEGF除了导致角膜和虹膜新生血管形成外,还会导致视网膜新生血管形成。视网膜新生血管形成源自浅层和深层毛细血管床。这些数据表明,Ang2可提高视网膜血管对VEGF血管生成作用的敏感性。

相似文献

1
Angiopoietin-2 enhances retinal vessel sensitivity to vascular endothelial growth factor.血管生成素-2增强视网膜血管对血管内皮生长因子的敏感性。
J Cell Physiol. 2004 Jun;199(3):412-7. doi: 10.1002/jcp.10442.
2
Increased expression of VEGF in retinal pigmented epithelial cells is not sufficient to cause choroidal neovascularization.视网膜色素上皮细胞中血管内皮生长因子(VEGF)表达增加不足以引起脉络膜新生血管形成。
J Cell Physiol. 2004 Dec;201(3):393-400. doi: 10.1002/jcp.20110.
3
Different effects of angiopoietin-2 in different vascular beds: new vessels are most sensitive.血管生成素-2在不同血管床中的不同作用:新血管最为敏感。
FASEB J. 2005 Jun;19(8):963-5. doi: 10.1096/fj.04-2209fje. Epub 2005 Mar 31.
4
Intraocular gutless adenoviral-vectored VEGF stimulates anterior segment but not retinal neovascularization.眼内无载体腺病毒载体血管内皮生长因子刺激眼前节而非视网膜新生血管形成。
J Cell Physiol. 2004 Jun;199(3):399-411. doi: 10.1002/jcp.10441.
5
Angiopoietin 1 prevents retinal detachment in an aggressive model of proliferative retinopathy, but has no effect on established neovascularization.血管生成素1在增殖性视网膜病变的侵袭性模型中可预防视网膜脱离,但对已形成的新生血管没有作用。
J Cell Physiol. 2005 Jul;204(1):227-35. doi: 10.1002/jcp.20292.
6
Early vascular and neuronal changes in a VEGF transgenic mouse model of retinal neovascularization.视网膜新生血管形成的VEGF转基因小鼠模型中的早期血管和神经元变化。
Invest Ophthalmol Vis Sci. 2006 Oct;47(10):4638-45. doi: 10.1167/iovs.06-0251.
7
Impaired pericyte recruitment and abnormal retinal angiogenesis as a result of angiopoietin-2 overexpression.血管生成素-2过表达导致周细胞募集受损和视网膜血管生成异常。
Thromb Haemost. 2007 Jan;97(1):99-108.
8
Remodeling retinal neovascularization by ALK1 gene transfection in vitro.体外通过ALK1基因转染重塑视网膜新生血管形成
Invest Ophthalmol Vis Sci. 2008 Oct;49(10):4553-60. doi: 10.1167/iovs.07-0995.
9
Intraocular expression of endostatin reduces VEGF-induced retinal vascular permeability, neovascularization, and retinal detachment.内皮抑素的眼内表达可降低血管内皮生长因子(VEGF)诱导的视网膜血管通透性、新生血管形成及视网膜脱离。
FASEB J. 2003 May;17(8):896-8. doi: 10.1096/fj.02-0824fje. Epub 2003 Mar 28.
10
Angiopoietin-2 plays an important role in retinal angiogenesis.血管生成素-2在视网膜血管生成中起重要作用。
J Cell Physiol. 2002 Aug;192(2):182-7. doi: 10.1002/jcp.10128.

引用本文的文献

1
Switching to faricimab alleviates persistent subretinal fluid and pigment epithelial detachment in neovascular age-related macular degeneration.转换为法西单抗可减轻新生血管性年龄相关性黄斑变性中的持续性视网膜下液和色素上皮脱离。
Jpn J Ophthalmol. 2025 Aug 22. doi: 10.1007/s10384-025-01264-6.
2
Recurrent uveitic macular edema managed with intravitreal faricimab injection.玻璃体内注射法西单抗治疗复发性葡萄膜炎性黄斑水肿。
J Ophthalmic Inflamm Infect. 2025 Mar 13;15(1):25. doi: 10.1186/s12348-025-00478-6.
3
Ocular Pharmacodynamics of Intravitreal Faricimab in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema.
玻璃体内 faricimab 治疗新生血管性年龄相关性黄斑变性或糖尿病性黄斑水肿患者的眼部药效动力学。
Transl Vis Sci Technol. 2024 Nov 4;13(11):13. doi: 10.1167/tvst.13.11.13.
4
Switch to faricimab after initial treatment with aflibercept in eyes with neovascular age-related macular degeneration.在新生血管性年龄相关性黄斑变性的眼中,初始治疗采用阿柏西普后转换为 faricimab。
Int Ophthalmol. 2024 Sep 5;44(1):369. doi: 10.1007/s10792-024-03297-1.
5
Three-month outcomes of treatment with faricimab or aflibercept for neovascular age-related macular degeneration: a propensity score matching study in a Japanese population.法西单抗或阿柏西普治疗新生血管性年龄相关性黄斑变性的三个月疗效:一项日本人群的倾向评分匹配研究
Graefes Arch Clin Exp Ophthalmol. 2024 Dec;262(12):3971-3978. doi: 10.1007/s00417-024-06582-y. Epub 2024 Jul 29.
6
Faricimab for neovascular age-related macular degeneration and diabetic macular edema: from preclinical studies to phase 3 outcomes.法西单抗治疗新生血管性年龄相关性黄斑变性和糖尿病性黄斑水肿:从临床前研究到 3 期结果。
Graefes Arch Clin Exp Ophthalmol. 2024 Nov;262(11):3437-3451. doi: 10.1007/s00417-024-06531-9. Epub 2024 Jun 7.
7
Factors Associated with Success of Switching to Faricimab for Neovascular Age-Related Macular Degeneration Refractory to Intravitreal Aflibercept.与玻璃体腔注射阿柏西普难治的新生血管性年龄相关性黄斑变性转换为注射法西单抗治疗成功相关的因素。
Life (Basel). 2024 Apr 4;14(4):476. doi: 10.3390/life14040476.
8
Bispecific VEGF-A and Angiopoietin-2 Antagonist RO-101 Preclinical Efficacy in Model of Neovascular Eye Disease.双特异性血管内皮生长因子-A和血管生成素-2拮抗剂RO-101在新生血管性眼病模型中的临床前疗效
Ophthalmol Sci. 2024 Jan 18;4(4):100467. doi: 10.1016/j.xops.2024.100467. eCollection 2024 Jul-Aug.
9
Six-month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age-related macular degeneration.在新生血管性年龄相关性黄斑变性的难治性病例中从阿柏西普转换为 faricimab 的 6 个月结果。
Graefes Arch Clin Exp Ophthalmol. 2024 Jan;262(1):43-51. doi: 10.1007/s00417-023-06222-x. Epub 2023 Sep 5.
10
Twenty Years of Anti-Vascular Endothelial Growth Factor Therapeutics in Neovascular Age-Related Macular Degeneration Treatment.抗血管内皮生长因子治疗在新生血管性年龄相关性黄斑变性治疗中的二十年。
Int J Mol Sci. 2023 Aug 21;24(16):13004. doi: 10.3390/ijms241613004.